Metabolic Pathway Inhibition in Liver Cancer.
Liver cancer is fundamentally physiologically different from the surrounding liver tissue. Despite multiple efforts to target the altered signaling pathways created by oncogenic mutations, not many have focused on targeting the altered metabolism that allows liver cancer to develop and grow. Still to be resolved is the question of whether the altered metabolic pathways in this cancer differ enough from the surrounding noncancerous cells to allow for the development of potent and specific compounds. Clinical studies of metabolic modulators would provide some more information with regard to the feasibility of this approach. Furthermore, as it appears that oncogenic signaling is essential to this cancer's altered metabolism, it stands to reason that targeting this altered signaling may allow the exploitation of specific metabolic vulnerabilities in combination with other drugs for enhanced efficacy. The identification of biomarkers of metabolic sensitivity will also be essential to determine whether these drugs will have the desired effect.
1 Department of Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Ali
A
Zarrinpar
D000970:Antineoplastic Agents / Q000494:pharmacology*; D055808:Drug Discovery / Q000379:methods* / Q000639:trends; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D053858:Metabolic Networks and Pathways / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects*
D000970:Antineoplastic Agents
automated biology; genomics; molecular biology; proteomics